Immunotherapy and immunoevasion of colorectal cancer

Simple item page
dc.contributor.authorAl Zein, Mohammad
dc.contributor.authorBoukhdoud, Mona
dc.contributor.authorShammaa, Hadi
dc.contributor.authorMouslem, Hadi
dc.contributor.authorEl Ayoubi, Lemir Majed
dc.contributor.authorIratni, Rabah
dc.contributor.authorIssa, Khodr
dc.contributor.authorKhachab, Maha Y.
dc.contributor.authorAssi, Hazem I.
dc.contributor.authorSahebkar, Amirhossein
dc.contributor.authorEid, Ali H.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentPharmacology and Toxicology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:44:54Z
dc.date.available2025-01-24T11:44:54Z
dc.date.issued2023
dc.description.abstractThe tremendous success of immunotherapy in clinical trials has led to its establishment as a new pillar of cancer therapy. However, little clinical efficacy has been achieved in microsatellite stable colorectal cancer (MSS-CRC), which constitutes most CRC tumors. Here, we discuss the molecular and genetic heterogeneity of CRC. We review the immune escape mechanisms, and focus on the latest advances in immunotherapy as a treatment modality for CRC. By providing a better understanding of the tumor microenvironment (TME) and the molecular mechanisms underlying immunoevasion, this review offers an insight into developing therapeutic strategies that are effective for patients with various subsets of CRC. © 2023 Elsevier Ltd
dc.identifier.doihttps://doi.org/10.1016/j.drudis.2023.103669
dc.identifier.eid2-s2.0-85164991924
dc.identifier.pmid37328052
dc.identifier.urihttp://hdl.handle.net/10938/30507
dc.language.isoen
dc.publisherElsevier Ltd
dc.relation.ispartofDrug Discovery Today
dc.sourceScopus
dc.subjectAdoptive cell therapy
dc.subjectCancer vaccines
dc.subjectColorectal cancer
dc.subjectCtla-4
dc.subjectImmune checkpoint inhibitor
dc.subjectPd-1
dc.subjectColorectal neoplasms
dc.subjectHumans
dc.subjectImmunotherapy
dc.subjectTreatment outcome
dc.subjectTumor microenvironment
dc.subjectCancer vaccine
dc.subjectProgrammed death 1 receptor
dc.subjectAdaptive immunity
dc.subjectAdoptive immunotherapy
dc.subjectAntigenic escape
dc.subjectCancer classification
dc.subjectCancer immunotherapy
dc.subjectCell transfer
dc.subjectConsensus
dc.subjectDown regulation
dc.subjectFood and drug administration
dc.subjectHla system
dc.subjectHuman
dc.subjectImmune evasion
dc.subjectImmune response
dc.subjectInnate immunity
dc.subjectMicrosatellite instability
dc.subjectReview
dc.subjectT lymphocyte activation
dc.subjectTumor immunity
dc.subjectColorectal tumor
dc.subjectGenetics
dc.titleImmunotherapy and immunoevasion of colorectal cancer
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2023-536.pdf
Size:
2.63 MB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine
Pharmacology and Toxicology